Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

INTRODUCTION: Immune-checkpoint inhibitors (ICIs) are transforming the modern era of cancer therapy. As new treatment options are becoming available, new patterns of disease behavior are manifesting. One such phenomenon, known as hyperprogressive disease (HPD), is a rare complication resulting in ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasparian, Saro, Gentille, Cesar, Burns, Ethan, Bernicker, Eric H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474421/
https://www.ncbi.nlm.nih.gov/pubmed/34589924
http://dx.doi.org/10.1016/j.jtocrr.2020.100017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474421/
https://www.ncbi.nlm.nih.gov/pubmed/34589924
http://dx.doi.org/10.1016/j.jtocrr.2020.100017

Ejemplares similares